Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Cash & Equivalents (2022 - 2025)

Neuraxis' Cash & Equivalents history spans 4 years, with the latest figure at $4.4 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 1577.79% year-over-year to $4.4 million; the TTM value through Sep 2025 reached $4.4 million, up 1577.79%, while the annual FY2024 figure was $3.7 million, 4605.79% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $4.4 million at Neuraxis, down from $6.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $6.0 million in Q2 2025 and bottomed at $51440.0 in Q2 2023.
  • The 4-year median for Cash & Equivalents is $761249.0 (2023), against an average of $1.8 million.
  • The largest annual shift saw Cash & Equivalents plummeted 69.03% in 2023 before it surged 4605.79% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $253699.0 in 2022, then tumbled by 69.03% to $78560.0 in 2023, then soared by 4605.79% to $3.7 million in 2024, then grew by 18.4% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for NRXS's Cash & Equivalents are $4.4 million (Q3 2025), $6.0 million (Q2 2025), and $2.0 million (Q1 2025).